<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011228</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-1090</org_study_id>
    <nct_id>NCT04011228</nct_id>
  </id_info>
  <brief_title>Epigenetics Based Diagnosis of Diabetes in Saliva and Blood Samples</brief_title>
  <official_title>Sex-specific Relationship of Epigenetics Based Modifications in the Saliva and Blood With the Occurence of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate epigenetics based modifications and biomarkers
      in the saliva and blood in diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 29, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Specifying the microRNAs in saliva in diabetic patients</measure>
    <time_frame>1 hour</time_frame>
    <description>Characterization of microRNAs in saliva of prediabetic and type 2 diabetic patients, as well as in women with gestational diabetes and healthy control subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of the percentage of liver fat with miRNA´s in diabetic patients.</measure>
    <time_frame>1 hours</time_frame>
    <description>Correlation of miRNA´s in the saliva with the amount of intrahepatic liver fat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the percentage of heart fat with miRNA´s in diabetic patients</measure>
    <time_frame>1 hour</time_frame>
    <description>Correlation of miRNA´s in the saliva with the amount of ectopic lipids in the heart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the percentage of the content of fat in the skeletal muscle with miRNA´s in diabetic patients.</measure>
    <time_frame>1 hour</time_frame>
    <description>Correlation of miRNA´s in the saliva with the amount of ectopic lipids in the skeletal muscle.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Prediabetic State</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Ectopic Lipids</condition>
  <condition>Epigenetics Based Modifications</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prediabetic patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Women with gestational diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant women without gestational diabetes</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>After a fasting period over night blood samples will be taken.</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Prediabetic patients</arm_group_label>
    <arm_group_label>Pregnant women without gestational diabetes</arm_group_label>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <arm_group_label>Women with gestational diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Saliva and blood samples</intervention_name>
    <description>After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Prediabetic patients</arm_group_label>
    <arm_group_label>Pregnant women without gestational diabetes</arm_group_label>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <arm_group_label>Women with gestational diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnet Resonance Spectroscopy</intervention_name>
    <description>The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Prediabetic patients</arm_group_label>
    <arm_group_label>Pregnant women without gestational diabetes</arm_group_label>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <arm_group_label>Women with gestational diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In the present study prediabetic patients, type 2 diabetic patients, women with gestational
        diabetes and healthy control subjects will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetic patients

          -  prediabetic patients

          -  women with gestational diabetes

          -  healthy control subjects without diabetes

          -  healthy pregnant women

        Exclusion Criteria:

          -  cancer disease

          -  infectious diseases such as hepatitis or HIV

          -  malignoms

          -  patients with claustrophoby
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Kautzky-Willer, Univ.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine III, Clinical Division of Endocrinology and Metabolism, Unit of Gender Medicine, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Kautzky-Willer, Univ.Prof.Dr.</last_name>
    <phone>+434040021260</phone>
    <email>alexandra.kautzky-willer@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Leutner, Dr.med.univ., MSc</last_name>
    <email>michael.leutner@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Kautzky-Willer, Univ.Prof.Dr.</last_name>
      <phone>+434040021260</phone>
      <email>alexandra.kautzky-willer@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>July 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Alexandra Kautzky-Willer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

